Mereo BioPharma
MREO
70 hedge funds and large institutions have $25.8M invested in Mereo BioPharma in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 35 closing their positions.
86% more call options, than puts
Call options by funds: $1.68M | Put options by funds: $902K
17% less funds holding
Funds holding: 84 → 70 (-14)
24.06% less ownership
Funds ownership: 63.04% → 38.98% (-24%)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
37% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 35
87% less capital invested
Capital invested by funds: $205M → $25.8M (-$179M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$19.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$15M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$8.29M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$2.57M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$33.6M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$19.4M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$16M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$11.4M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$9.42M |
MREO Hedge Fund Activity: Q4 2025 in Review
70 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2025, worth a combined $25.8M — down 87% from $205M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of MREO and 22 opened new positions — a net loss of 13 holders — while 20 trimmed existing stakes and 15 added.
The largest buyer was 683 Capital Management, adding an estimated $19.3M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $33.6M sold.
- 70 institutional investors held Mereo BioPharma (MREO) as of Q4 2025, down from 84 in Q3 2025.
- Funds reported $25.8M of Mereo BioPharma stock for Q4 2025, down 87% quarter-over-quarter.
- 22 funds opened new Mereo BioPharma positions in Q4 2025 and 35 closed out, a net change of -13 holders.
- The largest Mereo BioPharma buyer in Q4 2025 was 683 Capital Management, an estimated $19.3M added.
- The largest Mereo BioPharma seller in Q4 2025 was Janus Henderson Group, an estimated $33.6M sold.
Based on aggregated 13F filings for Q4 2025.